Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 7/20 | 0.36 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 4/20 | 0.33 |
| ▸ | TK1 | P04183 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21758938 | 0.77 | XDH (0.36) | XDHHPRT1MEN1KMT2APNP | |
| SCHEMBL24222060 | 0.75 | XDH (0.35) | XDHHPRT1MEN1KMT2APNP | |
| SCHEMBL18521149 | 0.74 | CDK1 (0.40) | XDHHPRT1MEN1KMT2APNP | |
| SCHEMBL24499589 | 0.74 | XDH (0.40) | XDHHPRT1MEN1KMT2APNP | |
| SCHEMBL22399377 | 0.74 | XDH (0.38) | XDHHPRT1MEN1KMT2APNP | |
| SCHEMBL22326728 | 0.73 | HPRT1 (0.44) | HPRT1PNPTK1 | |
| SCHEMBL21943372 | 0.71 | HPRT1 (0.39) | XDHHPRT1MEN1KMT2APNP | |
| SCHEMBL18521157 | 0.71 | CDK2 (0.46) | XDHHPRT1 | |
| SCHEMBL22571137 | 0.71 | PI4KA (0.41) | XDHMEN1KMT2APNPTK1 | |
| SCHEMBL21943158 | 0.71 | CDK1 (0.46) | HPRT1MEN1KMT2APNPTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210299155-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11376272-B2 | Methods of modulating immune activity | STING1, IRF3, CGAS | XDH 1755/4885HPRT1 1085/4885MEN1 4349/4885 |
| US-20210299155-A1 | METHODS OF MODULATING IMMUNE ACTIVITY | STING1, IRF3, CGAS | XDH 1739/4885HPRT1 1199/4885MEN1 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.